2M.D. Associate Professor, Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY
3M.D. Associate Professor, Yıldırım Bayazıt University Faculty of Medicine, Department of Ophthalmology, Ankara/TURKEY
4M.D. Professor, Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY Purpose: To evaluate the effect of initial central foveal thickness (CFT) on the anatomical and visual prognosis on intravitreal ranibizumab treatment for diabetic macular edema (DME).
Materials and Methods: Patients received intravitreal ranibizumab treatment for DME and having follow-up at least 6 months were evaluated. The demographic features, the CFT and best corrected visual acuity (BCVA) initially, at 3 month, at 6 month and at last follow up was recorded. The cases having CFT less than 400 ?m (group 1) and having CFT 400 ?m and more (group 2) were compared according to anatomical and functional outcomes.
Results: The mean follow up period of 35 eyes in group 1 and 47 eyes in group 2 was 16.49±7.58 months. The CFT initially, at 3 month, at 6 month and at last follow up in group 1 was 345.06±44.38 ?m, 299.14±78.8 ?m, 315.83±98.6 ?m, 277.47±85 ?m and in group 2, 510.23±85.16 ?m, 368.64±138.4 ?m, 380.30±145.1 ?m and 322.23±134.15 mm respectively. There was no statistical significant difference between groups at last follow up. The BCVA initially, at 3 month, at 6 month and at last follow up in group 1 was 0.63±0.47 logMar, 0.5±0.5 logMar, 0.38±0.43 logMar, 0.36±0.48 logMar and in group 2, 0.72±0.4 logMar, 0.58±0.5 logMar, 0.58±0.5 logMar and 0.55±0.42 logMar respectively. The difference between groups at last follow up was statistical significant.
Conclusion: The beginning CFT may be a factor affecting adversely the visual prognosis. In cases with high macular thickness, successful anatomic results can be obtained.
Keywords : Diabetic macular edema, ranibizumab, optical coherence tomography